Steatohepatitis
Metabolic surgery slashed risk for adverse outcomes in MASH-related cirrhosis, obesity
Metabolic surgery significantly lowered risk for major adverse liver outcomes vs. nonsurgical management among patients with obesity and compensated cirrhosis from metabolic dysfunction-associated steatohepatitis, according to study data.
Endoscopic sleeve gastroplasty ‘effective alternative’ for MASH, obesity management
Endoscopic sleeve gastroplasty with lifestyle intervention was more effective than lifestyle changes alone in achieving weight loss and histological improvement in patients with metabolic dysfunction-associated steatohepatitis and obesity.
VIDEO: FAST, Agile 3+ scores may predict treatment benefit in MASH, advanced fibrosis
SAN DIEGO — Both FibroScan-aspartate aminotransferase and Agile 3+ scores “performed well” in predicting risk for advanced fibrosis in patients with metabolic dysfunction-associated steatohepatitis who had been treated with pegozafermin.
Thyroid hormone receptor-beta agonist achieves ‘robust reduction’ in liver fat in MASH
SAN DIEGO — VK2809 demonstrated “robust reductions” in liver fat as early as 12 weeks in metabolic dysfunction-associated steatohepatitis, as well as MASH resolution and improvement in fibrosis by week 52, according to late-breaking data.
Novel farnesoid X receptor agonist safe, reduces liver fat content by up to 22.8% in MASH
SAN DIEGO — Once-daily FXR314 was well-tolerated and safely improved liver fat content and biochemical markers over 16 weeks in patients with metabolic dysfunction-associated steatohepatitis, according to research at The Liver Meeting.
Multiparametric MRI liver biomarkers predict those ‘likely to achieve’ MASH resolution
Changes in MRI-derived markers of iron-corrected T1 mapping and liver fat content appear effective at predicting histological response among patients treated for metabolic dysfunction-associated steatohepatitis, according to researchers.
FDA grants breakthrough status to Sagimet’s denifanstat to treat MASH with fibrosis
The FDA granted breakthrough designation to Sagimet Biosciences’ denifanstat for the treatment of patients with metabolic dysfunction-associated steatohepatitis and moderate to advanced fibrosis, according to a company press release.
Vitamin E improves serum inflammation markers, histology in MASLD
Vitamin E improved serum markers of liver inflammation and histology in patients with metabolic dysfunction-associated steatotic liver disease, according to results from a systematic review and meta-analysis.
Nearly 62% achieve MASH resolution without worsening of fibrosis with tirzepatide
Patients with metabolic dysfunction-associated steatohepatitis and advanced fibrosis treated with tirzepatide achieved significant disease resolution without worsening of fibrosis, compared with those on placebo, according to research.
MASH patients with high BMI, weight respond ‘slightly better’ to higher Rezdiffra dose
Patients with metabolic dysfunction-associated steatohepatitis who weigh more than 100 kg or a BMI more than 35 kg/m² had “slightly better” response with a 100 mg dose of Rezdiffra, according to data presented at EASL Congress.